Fructose Extra-splanchnic Metabolism and Its Effects on Systemic Flux of Substrates (FruPP) (FruPP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03195062|
Recruitment Status : Completed
First Posted : June 22, 2017
Last Update Posted : October 18, 2018
In parallel to the dramatic rise in metabolic diseases and diabetes observed over the past fifty years, the generalization of added sugar in processed food led to a marked increase in fructose consumption in almost all countries, and epidemiological studies demonstrated that the consumption of sugar-sweetened beverage (containing at least 50% of fructose) is associated with the development of diabetes, hepatic steatosis, dyslipidemia and obesity.
The objective of the study is to measure the amount of fructose that escape first-pass hepatic extraction after oral ingestion (fructose+glucose), and gain insights into its metabolic fates with the use of tracers.
|Condition or disease||Intervention/treatment||Phase|
|Test Meal||Other: Test meal||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Fructose Extra-splanchnic Metabolism and Its Effects on Systemic Flux of Substrates (FruPP)|
|Actual Study Start Date :||March 23, 2017|
|Actual Primary Completion Date :||June 30, 2018|
|Actual Study Completion Date :||August 31, 2018|
Experimental: Test meal
The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
Other: Test meal
Liquid test meal (fructose+glucose)
- Measurement of the amount of fructose that escape first-pass hepatic extraction after oral ingestion. [ Time Frame: The quantity of 13C fructose will be calculated, during the post prandial period, until 240 min. ]Calculation with 13C fructose enrichment in blood samples at T0; 30; 60; 90; 120; 150; 180; 210 and 240 min.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03195062
|University of Lausanne|
|Lausanne, Switzerland, 1005|